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Introduction {#sec001}
============

The factors that contribute to an increased susceptibility to fungal infection have been illuminated through the study of patients with primary and secondary immunodeficiencies \[[@pone.0155059.ref001], [@pone.0155059.ref002]\]. These studies have evaluated individuals with primary immunodeficiencies such as autosomal dominant STAT3 deficient Hyper IgE Syndrome (AD-HIES) and autosomal dominant STAT1 gain of function Chronic Mucocutaneous Candidiasis (AD-CMC) \[[@pone.0155059.ref003], [@pone.0155059.ref004]\], demonstrating a significant impairment of systemic Th17 immunity \[[@pone.0155059.ref005], [@pone.0155059.ref006]\]. Th17 cells are typically αβ^+^, CD4^+^ polyclonal T cells that are able to produce the key effector cytokines IL-17A/F and IL-22. These cytokines amplify mucosal responses through an action upon epithelial cells that produce important neutrophil chemotactic factors and antimicrobial peptides \[[@pone.0155059.ref007]\]. Indeed, other primary immunodeficiencies that are selective for the absence of IL17F (autosomal dominant IL-17F deficiency) or lack a response to IL17 (autosomal recessive IL-17RA deficiency) further illustrate the importance of IL-17 production for control of bacterial (i.e. *S*. *aureus)* and fungal (i.e. *C*. *albicans)* infection \[[@pone.0155059.ref008]\]. The generation and maintenance of Th17 cells has been shown to be dependent on the cytokines IL-6, IL-23 and IL-1β. Certain secondary immunodeficiencies that can mimic aspects of HIES and CMC have been shown to have inhibitory autoantibodies to these key cytokines \[[@pone.0155059.ref009]\]. In particular, some thymoma patients have been noted to have biologically active antagonistic autoantibodies to the common IL-12/23 p40 subunit and to IL-17F, leading to Th17 deficiency \[[@pone.0155059.ref010]--[@pone.0155059.ref012]\].

In recent years, another important IL-17 producing subset of αβ T cells has been identified, namely Mucosal Associated Invariant T cells (MAITs) \[[@pone.0155059.ref013], [@pone.0155059.ref014]\]. MAIT cells are an example of an 'innate T cell' \[[@pone.0155059.ref015]--[@pone.0155059.ref017]\]. These T cells reside principally in tissues but can be identified in peripheral blood \[[@pone.0155059.ref018]\]. MAIT cells possess a semi-invariant T cell receptor which utilizes Vα7.2-Jα33, with a restricted use of certain Vβ family members (i.e. Vβ2 and Vβ13). These cells are CD161^++^, CD8^+^ or double negative, effector memory cells with chemokine receptor expression that directs tissue tropism \[[@pone.0155059.ref019]\]. Their antigen recognition is unique in being able to respond to bacterial and fungal vitamin B2 metabolites through presentation on MR-1 \[[@pone.0155059.ref020]\] or via indirect activation through IL-12 and IL-18 cytokines that act on constitutively expressed IL-12 and IL-18 receptors \[[@pone.0155059.ref021]\]. We evaluated the presence and function of these cells in two groups of well-characterized primary (HIES) and secondary immunodeficiency (thymoma) patients with conventional Th17 deficiency and susceptibility to fungal and bacterial disease.

Methods {#sec002}
=======

Subjects and sample preparation {#sec003}
-------------------------------

PBMC from 6 thymoma patients with autoantibodies to IL-12/23 p40 (thymoma positive), 4 thymoma patients without autoantibodies (thymoma negative), three HIES adults with confirmed STAT3 deficiency (V637M, R417S, G618D) and 16 adult controls were isolated using Ficoll (GE Health, UK) according to manufacturer protocol. All participants were free from infection at the time of analysis. Written Informed consents were obtained from all patients (REC13/2000 and REC09/H0502/4). Control samples were obtained from the National Blood Services UK. The study was carried out in accordance with the Declaration of Helsinki. The study was approved by the University of Southampton, School of Medicine ethics committee. (REC13/2000 and REC09/H0502/4).

Immunophenotyping {#sec004}
-----------------

PBMC were stained with the following antibodies: TCRC Pacific Blue, CD4 V500, V follow (Biolegend, UK), MR1 APC (26.5) (Biolegend, UK), CD3 PerCP, CD161 APC, CD8 APC-Cy7, CD19 APC-Cy7 and CD20 Pacific Blue. All antibodies were from BD biosciences unless specified. The samples were stained for 15 minutes at room temperature, processed and then analyzed on a FACS Canto II machine with FACS Diva software evaluation.

IL-17 and IFN-γ production by MAIT and conventional T cells {#sec005}
-----------------------------------------------------------

PMA (Sigma) and ionomycin (Sigma) were used for T cell activation. Briefly, PMA and ionomycin were incubated with PBMC for 6 hours at 37°C, GolgiStop was added after 1 hours of incubation. Cells were fixed and permeabilised by the BD Cytofix/Cytoperm Fixation/Permeabilisation Kit according to the manufacturer's instruction before staining with the phenotype marker together with IL-17A FITC (eBiosciences) and IFN-γ PE-Cy7 (BD Biosciences). Samples were analyzed on a FACS Canto II machine with FACS Diva software evaluation.

MAIT cell cytokine assessment {#sec006}
-----------------------------

Enriched MAIT cells population were sorted with affymetrix MagniSort system with Vα7.2 antibody (Purity\>98%). IL-12 (50ng/ml) (Peprotech, UK) and IL18 (50ng/ml) (Peprotech, UK) were used to stimulate sorted MAIT across the clinical cohorts and controls for 24 hours. The supernatants were then collected and analysed with a cytokine human 25-plex (GM-CSF, TNF-n 25--1β, IL-4, IL-6, MIP-1α, IL-8, IL-15, IFN-α, IL-2R, IP-10, MIP-1β, Eotaxin, RANTES, MIG, IL-12(p40/p70), IL-1RA, IFN-γ, IL-13, MCP-1, IL-7, IL-17, IL-10, IL-5, IL-2) on the Luminex system. 10,000 cells were added to each samples and cytokine values were normalised to the number of MAIT cells (Vα7.2+CD161++CD3+ cells/ Vα7.2+ve cells pre sort) present in this population.

Statistical analysis {#sec007}
--------------------

Kruskal--Wallis test were used for the statistical comparison across the groups.

Results and Discussion {#sec008}
======================

We identified MAIT cells through a sequential gating strategy that selected CD3+ T cells, conventional αβ T cells and finally Vα7.2/CD161^++^ cells. Many of these MAIT cells had a characteristic CD8αα phenotype. Healthy volunteers showed a distinctive cluster of Vα7.2/CD161^++^ MAIT cells ([Fig 1A](#pone.0155059.g001){ref-type="fig"}). Representative enumeration of MAIT cells from the clinical groups showed a notable reduction of MAIT cells in HIES and thymoma +ve patients ([Fig 1B](#pone.0155059.g001){ref-type="fig"}). We extended this phenotyping to our cohorts and found that the extent of MAIT deficiency were similar in the thymoma positive patients to that observed in HIES ([Fig 1C](#pone.0155059.g001){ref-type="fig"}). The mean percentage of MAIT cells in HIES was 0.57% (P\<0.005), and in the thymoma positive patients was 0.13% (P\< 0.0001) compared to 2.2% in healthy controls. In contrast, the MAIT population of thymoma negative patients was not significantly different from controls (0.93% vs 2.2%, p = 0.2). The MR1 expression on B cells and monocyte across the clinical groups was not significantly different to controls ([Fig 1D](#pone.0155059.g001){ref-type="fig"}).

![(A) MAIT identification strategy in a healthy control. MAIT cells were identified following sequential gating of CD3 and TCR αβ expression, prior to their Vα7.2 and CD161 co staining. (B) Representative MAIT enumeration from primary and secondary immunodeficiency groups. (C) Mean percentage of MAIT cells (Percentage of MAIT cells in αβ T cells) and conventional T cells (Percentage of conventional T cells in total T cells) present in controls (n = 16, range 1.3--3%), thymoma negative (n = 4, range 0.4--1.9%), thymoma positive (n = 6, range 0.1--0.2%), and HIES (n = 3, range 0.1--1.1%) patients. The percentages of MAIT cells were found to be significantly lower in thymoma positive and HIES patients compared to the healthy controls (\*P\<0.0001). (D) Representative MR1 expression on control B cell population. Level of MR1 expression on B cell population was not significantly different across the clinical groups.](pone.0155059.g001){#pone.0155059.g001}

In agreement with previous studies \[[@pone.0155059.ref008], [@pone.0155059.ref012], [@pone.0155059.ref022]\], HIES patients showed a profoundly reduced number of conventional Th17 cells ([Fig 2A and 2B](#pone.0155059.g002){ref-type="fig"}) (0.2% vs 1.28%, P\<0.03). Within the thymoma cohorts a significant reduction in the Th17 subset was only seen in those with IL-12/23 autoantibodies ([Fig 2A and 2B](#pone.0155059.g002){ref-type="fig"}) (0.3% vs 1.28%, P\<0.01). Similarly both HIES and thymoma positive patients showed significant reductions in IL-17A producing MAIT cell populations ([Fig 2A and 2B](#pone.0155059.g002){ref-type="fig"}). This reduction of IL-17A production from this unconventional T cell subset led to a more extensive IL-17A T cell deficiency in both HIES and thymoma positive patients ([Fig 2B](#pone.0155059.g002){ref-type="fig"}).

![(A) Intracellular cytokine production of Il-17 and IFN-γ by MAIT and conventional T cells in representative control and patient groups. (B) Mean percentage of IL-17 and IFN-γ T cells (MAIT and conventional) in controls and patient groups. The percentage of IL-17 conventional and MAIT cells was significantly reduced in the thymoma positive, HIES patients (\*P\<0.03). MAIT IFN-γ production was lower in HIES and thymoma positive patients. (C) IFN-γ assessment of enriched MAIT cells across the clinical cohorts following IL-12/18 stimulation.](pone.0155059.g002){#pone.0155059.g002}

In agreement with a previous study \[[@pone.0155059.ref019]\], MAIT cells did not proliferate following mitogen (PMA), TCR (anti-CD3/CD28) or specific innate signaling with IL-12/18 in patients and controls ([S1 Fig](#pone.0155059.s001){ref-type="supplementary-material"}). Recent studies by several groups have shown that MAIT cells can proliferate under bacteria stimulation. {Leeansyah, 2014 \#5;Kurioka, 2015 \#6;Leeansyah, 2015 \#7}. However, the cells used for these experiments were either pre-activated MAIT cells or fetal MAIT cells. We examined the cytokine production of Vα7.2+ cells through a novel approach involving the activation of enriched MAIT cells within the Vα7.2 population with the specific stimulation of IL-12/18 ([S3 Fig](#pone.0155059.s003){ref-type="supplementary-material"}). The majority of IFN-gamma production was identified in the CD161+Vα7.2+ MAIT cells. (Other cytokines were not evaluated). In agreement of the intracellular cytokine analysis, a reduction in IFN-γproduction was found in the HIES and thymoma patient with autoantibodies ([Fig 2C](#pone.0155059.g002){ref-type="fig"}). No significant differences were found in other cytokines across the groups ([S2 Fig](#pone.0155059.s002){ref-type="supplementary-material"}). IL-12/18 activation of MAIT cells did not induce cytokine production from 12 out of these 25 cytokines.

MAIT cells are tissue resident innate T cells that provide rapid cytokine production and have been shown to be important in various infectious diseases \[[@pone.0155059.ref016], [@pone.0155059.ref023], [@pone.0155059.ref024]\]. Study by Wilson et al. has found that IL-23 is one of the main cytokines responsible for maintaining the number of innate T cells i.e. MAIT cells and iNKT cells. \[[@pone.0155059.ref025]\] Our findings suggest that there is an additional impairment of MAIT cells in immunodeficiency disorders associated with impaired systematic Th17 immunity. During the review process of this paper Wilson et al \[[@pone.0155059.ref025]\] showed a quantitative deficiency in a larger group of AD-HIES patients with loss of qualitative function in IL17A and F production. Our work supports this observation and extends it to secondary immunodeficiencies such as the IL-23 autoantibody phenocopy of STAT-3 impairment for MAIT cell function. In accordance with this, the clinical course of our some of our thymoma positive patients was complicated by fungal and bacterial infections ([Table 1](#pone.0155059.t001){ref-type="table"}), suggesting that the clinical impact of this systemic and innate T cell deficiency may have functional importance. Further observations on other immunodeficiencies with similar clinical features and/or systemic Th17 deficiencies are required to better understand the role of innate and conventional T cell compartments in the protection against infectious disease. These observations require further evaluation in larger cohorts but our study highlights the importance of evaluating non-conventional T cell populations in different immunodeficiency disorders to better understand their potential functional role and association with characteristic clinical presentations.

10.1371/journal.pone.0155059.t001

###### Clinical details of primary and secondary immunodeficiencies associated with Th17 deficiency.

![](pone.0155059.t001){#pone.0155059.t001g}

  ----------------------------------- -------- ----- --------------------------- ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------- ----------- ------ ------------ ------ ------------ ---------
  **Primary Immunodeficiency**                                                                                                                                                                                                                                                                                                                                                                                                
  Patient                             Gender   Age   Autoantibodies to IL12/23   Autoimmune Disease                 Infections                                                                                                                                                                                                                                  T cells   T cells %   CD4    CD4cells %   CD8    CD8cells %   B cells
  HIES 1*STAT3 c*.*1909G\>A V637M*    F        30    \-                          \-                                 Recurrent bacterial ear, chest and sinus infections (childhood onset) Recurrent *Staphylococcal Aureus* skin infections and deep tissue abscess Bronchiectasis, Lung cysts and Pneumatoceles Recurrent oral candidiasis (childhood onset)   1420      79          900    50           380    21           180
  HIES 2 *STAT3 c*.*1251A\>T R417S*   F        47    \-                          \-                                 Recurrent bacterial chest infections (Childhood onset) Recurrent *Aspergillus Fumigatis* chest infections Recurrent oral candidiasis (childhood onset) Bronchiectasis                                                                       750↓      68          570    52           140↓   12.7         80↓
  HIES 3 *STAT3 c*.*1853G\>A G618D*   M        43    \-                          \-                                 Pneumocystis jirovecii pneumonia Recurrent *Staphylococcal Aureus* skin infections (childhood onset) Recurrent bacterial ear, chest and sinus infections (childhood onset) Bronchiectasis and lung cysts                                    1480      78          860    45           570    30           240
  ** Secondary Immunodeficiency **                                                                                                                                                                                                                                                                                                                                                                                            
  P1                                  F        74    \-                          \-                                 \-                                                                                                                                                                                                                                          1182      70          1003   85           150↓   12           524
  P2                                  F        64    \-                          Cerebellar Degeneration            \-                                                                                                                                                                                                                                          569 ↓     52          309    54           246    43           132
  P3                                  F        53    \-                          Myasthenia Gravis                  \-                                                                                                                                                                                                                                          558 ↓     70          268↓   48           276    49           112
  P4                                  M        61    \-                          \-                                 \-                                                                                                                                                                                                                                          1362      91          603    44           610    45           139
  P5                                  M        57    \+                          \-                                 \-                                                                                                                                                                                                                                          3110      86          1313   42           1465   47           844
  P6                                  F        62    \+                          Myasthenia Gravis                  Recurrent bacterial respiratory infections Bronchiectasis                                                                                                                                                                                   922       84          248↓   27           625    68           113
  P7                                  F        65    \+                          Myasthenia Gravis Crohns Disease   \-                                                                                                                                                                                                                                          1341      71          487    36           431    32           241
  P8                                  M        66    \+                          Autoimmune enteropathy             Oesophageal Candidiasis                                                                                                                                                                                                                     1847      80          1103   60           613    33           225
  P9                                  F        73    \+                          \-                                 Recurrent bacterial respiratory infections Recurrent *Herpes Simplex* keratitis                                                                                                                                                             1663      79          531    32           1089   66           201
  P10                                 F        64    \+                          \-                                 \-                                                                                                                                                                                                                                          243↓      35          97↓    40           139↓   57           50↓
  ----------------------------------- -------- ----- --------------------------- ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------- ----------- ------ ------------ ------ ------------ ---------

Supporting Information {#sec009}
======================

###### Proliferation of MAIT cells by anti-CD3/CD28 and IL-12/18.

(PDF)

###### 

Click here for additional data file.

###### Cytokine production by enriched MAIT cells following IL-12/IL-18 stimulation.

(PDF)

###### 

Click here for additional data file.

###### IFN-gamma production by MAIT cells following IL-12/IL-18 stimulation.

(PDF)

###### 

Click here for additional data file.
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